华东医药2024年营收净利双增长 研发投入持续加码

Core Insights - Huadong Medicine achieved record performance in 2024, with total revenue of 41.906 billion yuan, a year-on-year increase of 3.16%, and a net profit attributable to shareholders of 3.512 billion yuan, up 23.72% [1] - The company announced a cash dividend plan for 2024, expecting to distribute 1.017 billion yuan [1] - The pharmaceutical industrial segment showed robust growth, with sales revenue of 13.811 billion yuan, a year-on-year increase of 13.05%, and a net profit of 2.876 billion yuan, up 29.04% [1] Research and Development - Huadong Medicine increased its R&D investment in the pharmaceutical industrial sector to 2.678 billion yuan, a year-on-year growth of 16.77%, with direct R&D expenses of 1.770 billion yuan, up 10.63% [2] - Direct R&D expenses accounted for 12.91% of pharmaceutical industrial revenue [2] - The company is actively integrating AI technology to enhance drug development and production efficiency [2] Aesthetic Medicine and Microbiology - The aesthetic medicine segment performed steadily, with subsidiary Xinkeli Aesthetics achieving revenue of 1.139 billion yuan, a year-on-year increase of 8.32% [2] - Huadong Medicine has developed 40 high-end aesthetic products, with 26 already launched internationally, enhancing its global market presence [2] - The industrial microbiology segment reported sales revenue of 0.711 billion yuan, a year-on-year growth of 43.12% [2]